Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about FULC, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Losmapimod | Facioscapulohumeral Muscular Dystrophy (FSHD) | Phase 3 · NCT05397470 | Terminated |
| ACE393 | Campylobacter Infection | Phase 2 · NCT00859716 | Unknown |
| Pociredir | Sickle Cell Disease | Phase 2 · NCT07401823 | Terminated |
| FTX-6058 - Two Dosing Periods | Healthy Adult Subjects | Phase 1 · NCT04586985 | Completed |
| FTX-6058 / Midazolam Syrup | Healthy Adult Subjects | Phase 1 · NCT04586985 | Completed |
| Losmapimod one 15 mg oral tablet | Healthy Adult Subjects | Phase 1 · NCT05002231 | Completed |
| Losmapimod two 7.5 mg oral tablets | Healthy Adult Subjects | Phase 1 · NCT05002231 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
FULC holds $306.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $14.7M/quarter from operations, an estimated runway of 62.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 39 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when FULC files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Kevin Tang 10% owner |
Insider | 7,080,945 | 9.27% | 2026-07-16 |
| TANG CAPITAL MANAGEMENT, LLC | 5%+ holder (13G) | 6,913,329 | 9.05% | 2026-07-13 |
| EcoR1 Capital, LLC | Institution (13G, 5%+) | 6,803,785 | 8.91% | 2026-09-30 |
| ADAR1 Capital Management, LLC | Institution (13G, 5%+) | 6,648,027 | 8.70% | 2026-09-30 |
| Nantahala Capital Management, LLC | Institution (13G, 5%+) | 6,575,352 | 8.61% | 2026-09-30 |
| BlackRock Portfolio Management LLC | Institution (13G, 5%+) | 6,155,437 | 8.06% | 2026-09-30 |
| RA CAPITAL MANAGEMENT, L.P. 10% owner |
Insider | 6,053,960 | 7.93% | 2025-12-08 |
| BlackRock, Inc. | Institution (13G, 5%+) | 4,802,880 | 6.29% | 2026-06-30 |
| Robert J Gould Director · +68,000 options |
Insider | 454,864 | 0.60% | 2026-02-02 |
| Greg Tourangeau Principal Accounting Officer · +133,120 options |
Insider | 14,062 | 0.02% | 2025-05-08 |
| Alan Ezekowitz Director · +68,000 options |
Insider | 10,927 | 0.01% | 2026-06-26 |
| Curtis Gale Oltmans Chief Legal Officer · +395,000 options |
Insider | 10,252 | 0.01% | 2025-12-15 |
Share count 76,381,948 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for FULC and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →